Roche Says Product Launches, Investments Go Unabated In India Irrespective Of Patent Controversies; Speaks Out On Patient Access Programs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Battling controversial patent litigations has neither deterred Swiss drug maker Roche from introducing new drugs in the Indian market nor has the company held back investments for growth in the country in fear of debatable intellectual property issues. That direct message was sent across by Roche India's Managing Director Girish Telang as he stressed hard to prove that his company had not exorbitantly priced a range of life saving drugs